Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (11534)	11/20/1997 1:10:00 PM
From: Harold Conn	Respond to of 32384

Maybe old news - Jim Jubak mentions LGND - look near the bottom of the article: techstocks.com Harold Conn

To: Henry Niman who wrote (11534)	11/20/1997 3:03:00 PM
From: JOEBT1	Read Replies (1) \| Respond to of 32384

FWIW I'm buying LGND. We'll look back on this as a real buying opportunity. Once the ALRI deal is closed the arbitrage short selling will cease and the price should move to around 16---IMHO. The next piece of significant news should drive it to 18. Technically it's going be a battle to get it over 18 but institutional buying with more supporting news should do it by year end---just my view of our world.

To: Henry Niman who wrote (11534)	11/20/1997 3:25:00 PM
From: Andrew H	Respond to of 32384

Henry--any interest in calling IR in regard to the status of the ALRI deal, etc.? If not, I am willing. Anyone have any questions to suggest?

To: Henry Niman who wrote (11534)	11/20/1997 5:25:00 PM
From: Andrew H	Read Replies (1) \| Respond to of 32384

Looks like good news for LLY and could be a plus for the whole sector. Fast track status. Looks like drug has the added benefit of reducing "bad" choloesterol levels which should make it a real blockbuster. As usual, looks like Murphy was wrong (about the limitations, this time). >>Thursday November 20, 4:37 pm Eastern Time Company Press Release Lilly's Evista - raloxifene hydrochloride - Recommended for FDA Marketing Clearance for Prevention of Osteoporosis INDIANAPOLIS--(BW HealthWire)--Nov. 20, 1997--Eli Lilly and Company announced today that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration recommended Evista(R) (raloxifene hydrochloride) for marketing clearance for the prevention of postmenopausal osteoporosis. The committee's recommendation, although not binding, will be considered by the FDA in its final review of the New Drug Application (NDA) submitted by Lilly in June 1997. That same month, based on the potential therapeutic significance of Evista, the FDA placed the drug on a six-month, or priority, review schedule. This classification does not ensure a decision within that time frame, nor is it a guarantee of approval. Evista is among the first in a new class of drugs called selective estrogen receptor modulators (SERMs). SERMs are being studied for their selective ability to act like estrogen in some tissues but not in others. More than 13,000 women in 28 countries have participated in Evista clinical trials to date. Interim data from these trials, released in June and presented to the FDA advisory committee today, showed that Evista prevented bone loss in the total body, lower spine and hip and also significantly increased bone mineral density in these regions when compared with calcium-supplemented placebo. Studies to assess Evista's ability to prevent fractures in postmenopausal women with osteoporosis are ongoing and involve more than 7,700 women worldwide. Investigators are also studying Evista's effects on serum lipids (cholesterol and fatty substances). In clinical trials, Evista significantly reduced LDL, or ''bad'' cholesterol, and total cholesterol when compared with placebo. Evista also significantly reduced serum fibrinogen. It did not affect total HDL, or ''good'' cholesterol, or triglycerides. Evista did not stimulate uterine or breast tissue. In clinical trials, women taking Evista did not differ from women taking placebo with respect to adverse uterine tissue effects, uterine bleeding, or breast swelling, tenderness or pain. In addition, clinical studies reveal that, when compared with placebo, Evista did not increase the risk of endometrial or breast cancer. The majority of side effects reported during clinical trials were mild. The most commonly reported side effects were hot flashes and leg cramps; however, discontinuation rates were low and comparable with placebo. In addition, Evista was associated with an increase in venous thromboembolic events (VTEs), similar to reported rates for hormone replacement therapy (HRT). As a woman makes the natural transition through menopause and her ovaries stop producing estrogen, she faces an increasing number of long-term health risks, among them osteoporosis. According to the National Osteoporosis Foundation, 28 million Americans, 80 percent of them women, are at risk of developing osteoporosis, a disease in which bones become fragile and are more likely to break. During the first five years after menopause, a woman can lose as much as 25 percent of her bone mass.1 If not prevented or left untreated, osteoporosis can progress painlessly until a bone breaks. Lilly is a global research-based pharmaceutical corporation headquartered in Indianapolis, Ind., that is dedicated to creating and delivering innovative pharmaceutical-based health care solutions that enable people to live longer, healthier and more active lives. Women's health is a key area in which the company is focusing its efforts. <<